Are Mounjaro and Zepbound the same drug?

They contain the same active ingredient (tirzepatide) from the same manufacturer, but they are different FDA-approved products with different approved indications and labeling.

Which one will my insurance cover?

Plans typically cover Mounjaro when there is a documented type 2 diabetes diagnosis. Weight-management coverage, where it exists, generally applies to Zepbound. Check your plan’s formulary — see our insurance guide.

Comparison

Mounjaro vs. Zepbound: Side-by-Side Comparison

Mounjaro and Zepbound both contain tirzepatide and are both made by Eli Lilly. They are separate FDA-approved products with different approved indications: Mounjaro for type 2 diabetes, Zepbound for chronic weight management and obstructive sleep apnea.

Editorially reviewed by the editorial teamLast updated August 12, 2026

Side-by-side comparison

Mounjaro vs. Zepbound
	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
Drug class	Dual GIP and GLP-1 receptor agonist	Dual GIP and GLP-1 receptor agonist
Manufacturer	Eli Lilly and Company	Eli Lilly and Company
FDA status (for weight management)	FDA Approved for a Different IndicationNot approved for weight management	FDA ApprovedApproved for chronic weight management
Approved indications	Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes	Chronic weight management in adults with obesity (BMI ≥30), or overweight (BMI ≥27) with at least one weight-related condition, as an adjunct to a reduced-calorie diet and increased physical activity Moderate-to-severe obstructive sleep apnea in adults with obesity
Administration	Subcutaneous injection (prefilled pen)	Subcutaneous injection (prefilled pen or single-dose vial)
Frequency	Once weekly	Once weekly
Approval date	May 2022	November 2023 (weight management); December 2024 (obstructive sleep apnea)
Boxed warning	Yes — see drug page	Yes — see drug page
Common adverse reactions (from labeling)	Nausea, Diarrhea, Decreased appetite, Vomiting, Constipation, Dyspepsia (indigestion), Abdominal pain	Nausea, Diarrhea, Vomiting, Constipation, Abdominal pain, Dyspepsia (indigestion), Injection site reactions, Fatigue, Hypersensitivity reactions, Belching (eructation), Hair loss, GERD
Official information source	Prescribing information	Prescribing information

Every cell is drawn from the two medications’ FDA labeling as recorded on their individual pages: Mounjaro and Zepbound. Where labeling does not establish a fact, the cell says so.

Key differences

Same active ingredient: both are tirzepatide, a dual GIP and GLP-1 receptor agonist from Eli Lilly, injected once weekly.
Different approved uses: Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.
Weight management is NOT an FDA-approved use of Mounjaro.
Approval dates differ: Mounjaro May 2022; Zepbound November 2023 (weight management) and December 2024 (obstructive sleep apnea).
Zepbound is also supplied in single-dose vials sold through Lilly’s self-pay channel, in addition to prefilled pens.

Important safety differences

Both labels carry the same boxed warning regarding thyroid C-cell tumors in rodents and the same MTC/MEN 2 contraindications.
Both list predominantly gastrointestinal adverse reactions as most common; the exact lists and frequencies come from each product’s own trials and are not interchangeable.

Read both full labels

Summaries cannot substitute for the prescribing information. Both labels are linked in the table above and in Sources below.

Which one is right for you?

We can’t answer that, and neither can any website. Choosing between weight-management medications depends on your medical history, other conditions and medications, what your insurance covers, and how you tolerate a given drug — all of which require a licensed clinician who knows your case. What we can do is make sure the facts you bring to that conversation are accurate and traceable to their source.

Frequently asked questions

Are Mounjaro and Zepbound the same drug?: They contain the same active ingredient (tirzepatide) from the same manufacturer, but they are different FDA-approved products with different approved indications and labeling.
Which one will my insurance cover?: Plans typically cover Mounjaro when there is a documented type 2 diabetes diagnosis. Weight-management coverage, where it exists, generally applies to Zepbound. Check your plan’s formulary — see our insurance guide.

Sources

Mounjaro prescribing information (DailyMed, NIH) — DailyMed/NIH. Link last verified August 12, 2026.
Drugs@FDA database — FDA. Link last verified August 12, 2026.
Mounjaro official site (Eli Lilly) — Manufacturer. Link last verified August 12, 2026.
Zepbound prescribing information (DailyMed, NIH) — DailyMed/NIH. Link last verified August 12, 2026.
Zepbound official site (Eli Lilly) — Manufacturer. Link last verified August 12, 2026.

Not medical advice. WeightLossDrugsGuide is an independent educational publisher. We are not a pharmacy, a medical provider, or a telehealth clinic, and we do not provide personalized medical recommendations or dosing guidance. Information here summarizes official FDA labeling and other primary sources and may not reflect the most recent changes. Always talk with a licensed clinician about your own situation, and read the full prescribing information for any medication.